keyword
https://read.qxmd.com/read/38650397/epidemiology-clinical-characteristics-outcome-and-biofilm-forming-properties-in-candidaemia-a-single-centre-retrospective-4-year-analysis-from-hungary
#1
JOURNAL ARTICLE
Fruzsina Kovács, Noémi Balla, Aliz Bozó, Andrea Harmath, Ágnes Jakab, Zoltán Tóth, Fruzsina Nagy, László Majoros, Renátó Kovács
BACKGROUND: Candidaemia is a life-threatening disease that is associated with high mortality, especially in intensive care units (ICUs). The number of comprehensive studies dealing with the epidemiologic characteristics of biofilm-related properties is limited. OBJECTIVE: This study evaluated the clinical characteristics of candidaemia, to assess the biofilm-forming properties of isolates, and to identify the risk factors of mortality. PATIENTS AND METHODS: A total of 149 candidaemia episodes from the University of Debrecen, Clinical Centre, between January 2020 and December 2023 were investigated retrospectively...
April 2024: Mycoses
https://read.qxmd.com/read/38649005/long-term-remission-of-candidiasis-with-fermented-lingonberry-mouth-rinse-in-an-adult-patient-with-apeced
#2
Pirjo Pärnänen, Juho Suojanen, Mikael Laine, Timo Sorsa, Annamari Ranki
We report a long-term remission in candidiasis in a 57-year-old Finnish female with autoimmune polyendocrinopathy-candidiasis-ectodermal dystrophy (APECED) suffering from recurrent oral, esophageal, gastric, vaginal, and anal candidiasis since childhood. Candidiasis treatment with antifungal medicines fluconazole, itraconazole, posaconazole, voriconazole, caspofungin, nystatin or amphotericin-B during 2008-2021 had variable effects and intermittent development of antifungal resistance and hospital periods. The patient started using fermented lingonberry juice (FLJ) as a mouth rinse daily in April 2021...
April 20, 2024: International Journal of Infectious Diseases: IJID
https://read.qxmd.com/read/38647938/effect-of-fatty-acids-on-intracellular-pneumocandin-b-0-storage-in-the-fermentation-of-glarea-lozoyensis
#3
JOURNAL ARTICLE
Weiting Zhang, Ping Yi, Ying Zhou, Kai Yuan, Xiaojun Ji, Ping Song
The natural product pneumocandin B0 is the precursor of the antifungal drug caspofungin. To explore the relationship between pneumocandin B0 and oil. We found that the addition of 1 g/L of oil to the fermentation medium is more conducive to the production of pneumocandin B0 . The metabolic reaction mechanism was explored using different fatty acids and the results showed that stearic acid and acetic acid increased the total production of pneumocandin B0 by 22.98% and 9.08%, respectively, as well as increasing the content of intracellular lipid droplets...
September 19, 2023: Bioresources and Bioprocessing
https://read.qxmd.com/read/38646424/drug-drug-interaction-between-tacrolimus-and-caspofungin-in-chinese-kidney-transplant-patients-with-different-cyp3a5-genotypes
#4
JOURNAL ARTICLE
Yundi Zhang, Bowen Shen, Yue Li, Huiying Zong, Xiaoming Zhang, Xiaohong Cao, Fengxi Liu, Yan Li
BACKGROUND: The effect of drug-drug interaction between tacrolimus and caspofungin on the pharmacokinetics of tacrolimus in different CYP3A5 genotypes has not been reported in previous studies. OBJECTIVES: To investigate the effect of caspofungin on the blood concentration and dose of tacrolimus under different CYP3A5 genotypes. DESIGN: We conducted a retrospective cohort study in The First Affiliated Hospital of Shandong First Medical University and Shandong Provincial Qianfoshan Hospital from January 2015 to December 2022...
2024: Therapeutic Advances in Drug Safety
https://read.qxmd.com/read/38627248/comparison-of-fungemia-caused-by-candida-and-non-candida-rare-yeasts-a-retrospective-study-from-a-tertiary-care-hospital
#5
JOURNAL ARTICLE
Yasemin Oz, Mustafa Yılmaz, Tuba Bulduk, Mehmet Basayigit, Eren Gunduz, Selma Metintas
Although Candida species are the most common cause of fungemia, non-Candida rare yeasts (NCY) have been increasingly reported worldwide. Although the importance of these yeast infections is recognized, current epidemiological information about these pathogens is limited and they have variable antifungal susceptibility profiles. In this study, we aimed to evaluate the clinical characteristics for fungemia caused by NCY by comparing with candidemia. The episodes of NCY fungemia between January 2011 and August 2023 were retrospectively evaluated in terms of clinical characteristics, predisposing factor and outcome...
April 16, 2024: Medical Mycology
https://read.qxmd.com/read/38621582/niche-specific-microevolution-of-candida-glabrata-nakaseomyces-glabrata-during-an-infection
#6
JOURNAL ARTICLE
Ana L López-Marmolejo, Marco J Hernández-Chávez, Guadalupe Gutiérrez-Escobedo, M Selene Herrera-Basurto, Héctor M Mora-Montes, Alejandro De Las Peñas, Irene Castaño
Candida glabrata (Nakaseomyces glabrata) is an emergent and opportunistic fungal pathogen that colonizes and persists in different niches within its human host. In this work, we studied five clinical isolates from one patient (P7), that have a clonal origin, and all of which come from blood cultures except one, P7-3, obtained from a urine culture. We found phenotypic variation such as sensitivity to high temperature, oxidative stress, susceptibility to two classes of antifungal agents, and cell wall porosity...
April 13, 2024: Fungal Genetics and Biology: FG&B
https://read.qxmd.com/read/38601473/antifungal-effects-of-echinocandins-diminish-when-exposed-to-intestinal-lumen-contents-a-finding-with-potentially-significant-clinical-implications
#7
JOURNAL ARTICLE
Sepideh Mehravar, Gabriela S Leite, Mark Pimentel, Ali Rezaie
Echinocandins, a prominent class of antifungals, are known for their broad-spectrum activity and favorable safety profiles. However, their bioavailability and efficacy via oral route are suboptimal. In this study, caspofungin and micafungin, the two most commonly used echinocandins, were evaluated in various in vitro environments simulating intestinal lumen. The results revealed that while both antifungals are effective in standard medium, their efficacy significantly diminishes in the presence of human small bowel aspirates and bovine bile...
2024: Frontiers in Pharmacology
https://read.qxmd.com/read/38567615/analysis-of-candidemia-cases-in-a-city-hospital-during-the-covid-19-pandemic
#8
JOURNAL ARTICLE
O Ozalp, S Komec, M Unsel, A Gunduz, O Altuntas Aydin
OBJECTIVE: The frequency and mortality of candidemia remain important. Non-albicans Candida species such as C. auris are increasing. PATIENTS AND METHODS: A retrospective review of adult patients diagnosed with bloodstream infection due to Candida species in the 17 months between July 1, 2020, and December 1, 2021, was performed. Yeast colonies grown in culture were identified by matrix-assisted laser desorption/ionization time-of-flight. Antifungal susceptibility tests of Candida strains were performed with Sensititre YeastOne (TREK Diagnostic Systems Inc...
March 2024: European Review for Medical and Pharmacological Sciences
https://read.qxmd.com/read/38535591/antifungal-susceptibility-of-saccharomyces-cerevisiae-isolated-from-clinical-specimens
#9
JOURNAL ARTICLE
Aleksandra Górzyńska, Kamila Kondracka, Agnieszka Korzeniowska-Kowal, Urszula Nawrot
(1) Background: Despite being considered a non-pathogenic yeast, recently, a growing occurrence of Saccharomyces cerevisiae infections has been noted. There is little knowledge about the drug susceptibility of this species. Therefore, the objective of this research was to expand it and determine the drug susceptibility profile of a local collection of clinical isolates of this species. (2) Methods: This study contained 55 clinical isolates identified as Saccharomyces cerevisiae using the MALDI-TOF method. The susceptibility of Saccharomyces cerevisiae was tested to 10 antifungals (amphotericin B, flucytosine, fluconazole, voriconazole, posaconazole, micafungin, anidulafungin, caspofungin, and itraconazole) using MICRONAUT-AT tests and manogepix, a new drug, using the microdilution method according to EUCAST...
March 14, 2024: Pathogens
https://read.qxmd.com/read/38535232/-candida-albicans-genes-modulating-echinocandin-susceptibility-of-caspofungin-adapted-mutants-are-constitutively-expressed-in-clinical-isolates-with-intermediate-or-full-resistance-to-echinocandins
#10
JOURNAL ARTICLE
Anshuman Yadav, Sudisht K Sah, David S Perlin, Elena Rustchenko
The opportunistic fungus Candida albicans is the leading cause of invasive candidiasis in immune-compromised individuals. Drugs from the echinocandin (ECN) class, including caspofungin, are used as a first line of therapy against invasive candidiasis. The only known mechanism of clinical resistance to ECNs is point mutations in the FKS1 gene, which encodes the drug target. However, many clinical isolates developed decreased ECN susceptibilities in the absence of resistance-associated FKS1 mutations. We have identified 15 C...
March 19, 2024: Journal of Fungi (Basel, Switzerland)
https://read.qxmd.com/read/38535222/commercial-methods-for-antifungal-susceptibility-testing-of-saprophytic-molds-can-they-be-used-to-detect-resistance
#11
REVIEW
Paschalis Paranos, Ana Espinel-Ingroff, Joseph Meletiadis
Commercial tests are often employed in clinical microbiology laboratories for antifungal susceptibility testing of filamentous fungi. Method-dependent epidemiological cutoff values (ECVs) have been defined in order to detect non-wild-type (NWT) isolates harboring resistance mechanisms. We reviewed the literature in order to find studies where commercial methods were used to evaluate for in vitro susceptibility of filamentous fungi and assess their ability to detect NWT isolates according to the available ECVs...
March 14, 2024: Journal of Fungi (Basel, Switzerland)
https://read.qxmd.com/read/38535202/changing-epidemiology-of-clinical-isolates-of-candida-species-during-the-coronavirus-disease-2019-pandemic-data-analysis-from-a-korean-tertiary-care-hospital-for-6-years-2017-2022
#12
JOURNAL ARTICLE
Eun Jeong Won, Heungsup Sung, Mi-Na Kim
This study assessed the changes in Candida species distribution and antifungal susceptibility patterns during the coronavirus disease 2019 (COVID-19) pandemic compared with a pre-pandemic period in Korea. We retrospectively investigated the specimen, species type, and antifungal susceptibility of Candida isolates obtained between 2016 and 2022. Data between two periods were compared: 2016-2019 (pre-pandemic) and 2020-2022 (pandemic). We included 11,396 clinical isolates of Candida species (5137 isolates in the pre-pandemic and 6259 isolates in the pandemic)...
March 2, 2024: Journal of Fungi (Basel, Switzerland)
https://read.qxmd.com/read/38530040/efficacy-and-safety-of-caspofungin-for-the-treatment-of-invasive-pulmonary-aspergillosis-in-patients-with-chronic-obstructive-pulmonary-disease
#13
JOURNAL ARTICLE
Shaoqiang Li, Zhengtu Li, Penglei Wang, Yangqing Zhan, Jiaxing Xie, Feng Ye
OBJECTIVES: We assessed the efficacy of a 3-week primary or salvage caspofungin regimen in patients with chronic obstructive pulmonary disease (COPD) and concomitant proven or suspected invasive pulmonary aspergillosis (IPA). METHODS: Forty-four patients were treated with an initial loading caspofungin dose of 70 mg, followed by a daily dose of 50 mg for 20 days. The main efficacy endpoint was clinical effectiveness. Secondary endpoints included the clinical efficacy of caspofungin after 1 week, therapeutic efficacy based on the European Organization for Research and Treatment of Cancer and Mycoses Study Group Education and Research Consortium (EORTC/MSG) criteria, the sensitivity of different Aspergillus strains to caspofungin in vitro , and the safety of caspofungin...
March 2024: Journal of International Medical Research
https://read.qxmd.com/read/38526046/outcomes-by-candida-spp-in-the-restore-phase-3-trial-of-rezafungin-versus-caspofungin-for-candidemia-and-or-invasive-candidiasis
#14
JOURNAL ARTICLE
Jeffrey B Locke, Chris M Pillar, Mariana Castanheira, Cecilia G Carvalhaes, David Andes, Jalal A Aram, Christina Andrzejewski, Ken Bartizal, Anita F Das, Taylor Sandison, George R Thompson, Peter G Pappas
Rezafungin is a long-acting, intravenously administered echinocandin for the treatment of candidemia and invasive candidiasis (IC). Non-inferiority of rezafungin vs caspofungin for the treatment of adults with candidemia and/or IC was demonstrated in the Phase 3 ReSTORE study based on the primary endpoints of day 14 global cure and 30-day all-cause mortality. Here, an analysis of ReSTORE data evaluating efficacy outcomes by baseline Candida species is described. Susceptibility testing was performed for Candida species using the Clinical and Laboratory Standards Institute reference broth microdilution method...
March 25, 2024: Antimicrobial Agents and Chemotherapy
https://read.qxmd.com/read/38524068/antifungal-susceptibility-profile-of-clinical-and-environmental-isolates-of-aspergillus-species-from-a-tertiary-care-center-in-north-india
#15
JOURNAL ARTICLE
Manharpreet Kaur, Nidhi Singla, Deepak Aggarwal, Reetu Kundu, Neelam Gulati, Mani Bhushan Kumar, Satinder Gombar, Jagdish Chander
INTRODUCTION: Aspergillus species are ubiquitously found in the environment worldwide and are important causative agents for infection. Drug resistance among Aspergillus species is emerging, hence the present study was undertaken to look for antifungal susceptibility profiles of clinical and environmental isolates of Aspergillus species. MATERIALS AND METHODS: During the period from January 2018 to June 2019, a total of 102 Aspergillus isolates (40 clinical, 40 hospital, and 22 community environment) were tested for antifungal susceptibility testing for determination of minimum inhibitory concentration (MIC)/minimum effective concentration (MEC) as per Clinical and Laboratory Standards Institute (CLSI) M38-A3 method for itraconazole, voriconazole, amphotericin B, and caspofungin...
February 2024: Curēus
https://read.qxmd.com/read/38501836/evaluation-of-the-vitek-2-system-for-antifungal-susceptibility-testing-of-candida-auris-using-a-representative-international-panel-of-clinical-isolates-overestimation-of-amphotericin-b-resistance-and-underestimation-of-fluconazole-resistance
#16
JOURNAL ARTICLE
Maria Siopi, Ioannis Pachoulis, Sevasti Leventaki, Bram Spruijtenburg, Jacques F Meis, Spyros Pournaras, Georgia Vrioni, Athanasios Tsakris, Joseph Meletiadis
Although the Vitek 2 system is broadly used for antifungal susceptibility testing of Candida spp., its performance against Candida auris has been assessed using limited number of isolates recovered from restricted geographic areas. We therefore compared Vitek 2 system with the reference Clinical and Laboratory Standards Institute (CLSI) broth microdilution method using an international collection of 100 C . auris isolates belonging to different clades. The agreement ±1 twofold dilution between the two methods and the categorical agreement (CA) based on the Centers for Disease Control and Prevention's (CDC's) tentative resistance breakpoints and Vitek 2-specific wild-type upper limit values (WT-ULVs) were determined...
April 10, 2024: Journal of Clinical Microbiology
https://read.qxmd.com/read/38497911/rise-and-fall-of-caspofungin-the-current-status-of-caspofungin-as-a-treatment-for-cryptococcus-neoformans-infection
#17
REVIEW
Tawanny Kb Aguiar, Ana Cm Costa, Nilton As Neto, Daiane Ms Brito, Cleverson Dt Freitas, João Mm Neto, Felipe P Mesquita, Pedro Fn Souza
Antifungal infections are becoming a major concern to human health due to antimicrobial resistance. Echinocandins have been promising agents against resistant fungal infections, primarily caspofungin, which has a more effective mechanism of action than azoles and polyenes. However, fungi such as Cryptococcus neoformans appear to be inheritably resistant to these drugs, which is concerning due to the high clinical importance of C. neoformans . In this review, we review the history of C. neoformans and the treatments used to treat antifungals over the years, focusing on caspofungin, while highlighting the C...
March 18, 2024: Future Microbiology
https://read.qxmd.com/read/38489910/modeling-of-intravenous-caspofungin-administration-using-an-intestine-on-chip-reveals-altered-candida-albicans-microcolonies-and-pathogenicity
#18
JOURNAL ARTICLE
Tim Kaden, Raquel Alonso-Roman, Parastoo Akbarimoghaddam, Alexander S Mosig, Katja Graf, Martin Raasch, Bianca Hoffmann, Marc T Figge, Bernhard Hube, Mark S Gresnigt
Candida albicans is a commensal yeast of the human intestinal microbiota that, under predisposing conditions, can become pathogenic and cause life-threatening systemic infections (candidiasis). Fungal-host interactions during candidiasis are commonly studied using conventional 2D in vitro models, which have provided critical insights into the pathogenicity. However, microphysiological models with a higher biological complexity may be more suitable to mimic in vivo-like infection processes and antifungal drug efficacy...
March 9, 2024: Biomaterials
https://read.qxmd.com/read/38484343/the-first-case-of-isolation-of-magnusiomyces-capitatus-from-the-oral-cavity-of-an-addicted-patient
#19
JOURNAL ARTICLE
Aynaz Ghojoghi, Sadegh Khodavaisy, Ali Zarei Mahmoudabadi, Maryam Hatami, Mahnaz Fatahinia
Magnusiomyces capitatus (M. capitatus) is an emerging opportunistic yeast, rarely found as a causal agent of invasive fungal infection. In this study, we report a 31-year-old man infected with M. capitatus in the oral cavity, with a history of heroin and amphetamine abuse. M. capitatus was isolated through culture and microscopic analysis and identified by PCR amplification of the ITS DNA region. Based on the in vitro antifungal susceptibility test, the lowest MICs for M. capitatus were recorded for nystatin, itraconazole, and amphotericin, while higher MICs were observed for caspofungin and fluconazole...
February 29, 2024: Journal of Infection in Developing Countries
https://read.qxmd.com/read/38483681/pulmonary-surfactant-impacts-in-vitro-activity-of-selected-antifungal-drugs-against-candida-krusei-and-candida-albicans
#20
JOURNAL ARTICLE
Alina Nussbaumer-Pröll, Peter Matzneller, Sabine Eberl, Markus Zeitlinger
PURPOSE: This study investigates how surfactants affect the in-vitro anti-infective efficacy of micafungin, caspofungin, anidulafungin, and amphotericin B in treating pulmonary mycoses. METHODS: MIC values for antifungal agents were determined against Candida krusei (now Pichia kudriavzevii) ATCC 6258, Candida albicans ATCC 90028, and 18 clinical isolates using the broth microdilution method in RPMI medium, following EUCAST recommendations. MIC assays included testing with and without Curosurf® surfactant at 1 mg/mL for C...
March 14, 2024: European Journal of Clinical Microbiology & Infectious Diseases
keyword
keyword
54692
1
2
Fetch more papers »
Fetching more papers... Fetching...
Remove bar
Read by QxMD icon Read
×

Save your favorite articles in one place with a free QxMD account.

×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"

We want to hear from doctors like you!

Take a second to answer a survey question.